- Prevention of postoperative recurrence in Crohn’s disease: the never-ending story
-
Park JB, Park SH
- KMID: 2531980
- Intest Res.
- 2022 Jul;20(3):279-280.
- doi: 10.5217/ir.2022.00081
-
- CITED
-
- Close
- SHARE
-
- Close
- Colonic oncostatin M expression evaluated by immunohistochemistry and infliximab therapy outcome in corticosteroid-refractory acute severe ulcerative colitis
-
O’Connell J, Doherty J, Buckley A, Cormican D, Dunne C, Hartery K, Larkin J, MacCarthy F, McCormick P, McKiernan S, Mehigan B, Muldoon C, Ryan C, O’Sullivan J, Kevans D
- KMID: 2531992
- Intest Res.
- 2022 Jul;20(3):381-385.
- doi: 10.5217/ir.2021.00073
-
- CITED
-
- Close
- SHARE
-
- Close
- Endoscopic diagnosis and treatment of early colorectal cancer
-
Hong SW, Byeon JS
- KMID: 2531981
- Intest Res.
- 2022 Jul;20(3):281-290.
- doi: 10.5217/ir.2021.00169
Early colorectal cancer refers to cancer in the colorectum that is confined to the mucosa or submucosa and does not invade the muscularis propria, irrespective of lymph node or distant... -
- CITED
-
- Close
- SHARE
-
- Close
- Intestinal ultrasonography and fecal calprotectin for monitoring inflammation of ileal Crohn’s disease: two complementary tests
-
Paredes JM, Ripollés T, Algarra Á, Diaz R, Moreno N, Latorre P, Martínez MJ, Llopis P, López A, Moreno-Osset E
- KMID: 2531990
- Intest Res.
- 2022 Jul;20(3):361-369.
- doi: 10.5217/ir.2021.00126
Background/Aims: Tight control of inflammation and adjustment of treatment if activity persists is the current strategy for the management of Crohn’s disease (CD). The usefulness of fecal calprotectin (FC) in... -
- CITED
-
- Close
- SHARE
-
- Close
- Landscape of inflammatory bowel disease in Singapore
-
Low D, Swarup N, Okada T, Mizoguchi E
- KMID: 2531982
- Intest Res.
- 2022 Jul;20(3):291-296.
- doi: 10.5217/ir.2021.00089
Inflammatory bowel disease (IBD), primarily Crohn’s disease and ulcerative colitis, had been widely recognized to affect the Western population. However, the notable rise in prevalence of IBD in Asia, including... -
- CITED
-
- Close
- SHARE
-
- Close
- Endoscopy for assessment of mucosal healing in ulcerative colitis: time bound or response guided?
-
Sood A, Mahajan R, Singh A, Midha V, Mehta V
- KMID: 2531983
- Intest Res.
- 2022 Jul;20(3):297-302.
- doi: 10.5217/ir.2021.00099
The timing of colonoscopy in patients with active ulcerative colitis (UC) lacks coherence. The published guidelines and recommendations advocate time-bound colonoscopy in patients with active UC to assess for mucosal... -
- CITED
-
- Close
- SHARE
-
- Close
- Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn’s disease
-
Buisson A, Cannon L, Umanskiy K, Hurst RD, Hyman NH, Sakuraba A, Pekow J, Dalal S, Cohen RD, Pereira B, Rubin DT
- KMID: 2531984
- Intest Res.
- 2022 Jul;20(3):303-312.
- doi: 10.5217/ir.2021.00018
Background/Aims: We assessed the effectiveness of anti-TNF agents and its associated factors to prevent endoscopic and clinical postoperative recurrence (POR) in Crohn’s disease (CD). Methods: From a prospectively-maintained database, we... -
- CITED
-
- Close
- SHARE
-
- Close
- Update on SARS-CoV-2 vaccination of patients with inflammatory bowel disease: what clinicians need to know
-
Lee YJ, Kim SE, Park YE, Chang JY, Song HJ, Kim DH, Yang YJ, Kim BC, Lee JG, Yang HC, Myung SJ, Clinical Practice Guideline Committee of the Korean Association for the Study of Intestinal Diseases
- KMID: 2531993
- Intest Res.
- 2022 Jul;20(3):386-388.
- doi: 10.5217/ir.2020.00172
-
- CITED
-
- Close
- SHARE
-
- Close
- Risk factors for non-reaching of ileal pouch to the anus in laparoscopic restorative proctocolectomy with handsewn anastomosis for ulcerative colitis
-
Emoto S, Hata K, Nozawa H, Kawai K, Tanaka T, Nishikawa T, Shuno Y, Sasaki K, Kaneko M, Murono K, Iida Y, Ishii H, Yokoyama Y, Anzai H, Sonoda H, Ishihara S
- KMID: 2531985
- Intest Res.
- 2022 Jul;20(3):313-320.
- doi: 10.5217/ir.2020.00158
Background/Aims: Restorative proctocolectomy (RPC) with ileal pouch-anal anastomosis and handsewn anastomosis for ulcerative colitis requires pulling down of the ileal pouch into the pelvis, which can be technically challenging. We... -
- CITED
-
- Close
- SHARE
-
- Close
- Relationship between the gut microbiota and bile acid composition in the ileal mucosa of Crohn’s disease
-
Bamba S, Inatomi O, Nishida A, Ohno M, Imai T, Takahashi K, Naito Y, Iwamoto J, Honda A, Inohara N, Andoh A
- KMID: 2531991
- Intest Res.
- 2022 Jul;20(3):370-380.
- doi: 10.5217/ir.2021.00054
Background/Aims: Crosstalk between the gut microbiota and bile acid plays an important role in the pathogenesis of gastrointestinal disorders. We investigated the relationship between microbial structure and bile acid metabolism... -
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation of nutritional status using bioelectrical impedance analysis in patients with inflammatory bowel disease
-
Kim SH, Kim YS, Lee SH, Lee HM, Yoon WE, Kim SH, Myung HJ, Moon JS
- KMID: 2531986
- Intest Res.
- 2022 Jul;20(3):321-328.
- doi: 10.5217/ir.2021.00022
Background/Aims: Nutritional status influences quality of life among patients with inflammatory bowel disease (IBD), although there is no clear method to evaluate nutritional status in this setting. Therefore, this study... -
- CITED
-
- Close
- SHARE
-
- Close
- Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance
-
Nakamura S, Asano T, Tsuchiya H, Sugimoto K, Imai Y, Yokoyama S, Suzuki Y
- KMID: 2531987
- Intest Res.
- 2022 Jul;20(3):329-341.
- doi: 10.5217/ir.2021.00032
Background/Aims: Golimumab (GLM) is an anti-tumor necrosis factor-α drug approved for treating moderate-to-severe active ulcerative colitis (UC). A 52-week post-marketing surveillance (PMS) was initiated to evaluate its safety and effectiveness... -
- CITED
-
- Close
- SHARE
-
- Close
- A nationwide analysis on the influence of obesity in inflammatory bowel disease hospitalizations
-
Dahiya DS, Kichloo A, Wani F, Singh J, Solanki D, Shaka H
- KMID: 2531988
- Intest Res.
- 2022 Jul;20(3):342-349.
- doi: 10.5217/ir.2021.00046
Background/Aims: Proinflammatory cytokines released from adipocytes can influence the development, progression, and treatment of inflammatory bowel disease (IBD), and may be associated with worse clinical outcomes. Methods: For 2016–2018, we... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
-
Shin SY, Park SJ, Kim Y, Im JP, Kim HJ, Lee KM, Kim JW, Jung SA, Lee J, Kang SB, Shin SJ, Kim ES, Kim YS, Kim TO, Kim HS, Park DI, Kim HK, Kim ES, Kim YH, Kim DH, Teng D, Kim JH, Kim W, Choi CH, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases
- KMID: 2531989
- Intest Res.
- 2022 Jul;20(3):350-360.
- doi: 10.5217/ir.2021.00049
Background/Aims: This study assessed the efficacy and safety of adalimumab (ADA) and explored predictors of response in Korean patients with ulcerative colitis (UC). Methods: A prospective, observational, multicenter study was conducted... -
- CITED
-
- Close
- SHARE
-
- Close
